RT Journal Article
SR Electronic
T1 Prognostic value of <em>TP53</em>, <em>KRAS</em> and <em>EGFR</em> mutations in nonsmall cell lung cancer: the EUELC cohort
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 177
OP 184
DO 10.1183/09031936.00097311
VO 40
IS 1
A1 Chiara Scoccianti
A1 Aurélien Vesin
A1 Ghislaine Martel
A1 Magali Olivier
A1 Elisabeth Brambilla
A1 Jean-François Timsit
A1 Luca Tavecchio
A1 Christian Brambilla
A1 John K. Field
A1 Pierre Hainaut
A1 the European Early Lung Cancer Consortium
YR 2012
UL http://erj.ersjournals.com/content/40/1/177.abstract
AB Nonsmall cell lung cancer samples from the European Early Lung Cancer biobank were analysed to assess the prognostic significance of mutations in the TP53, KRAS and EGFR genes. The series included 11 never-smokers, 86 former smokers, 152 current smokers and one patient without informed smoking status. There were 110 squamous cell carcinomas (SCCs), 133 adenocarcinomas (ADCs) and seven large cell carcinomas or mixed histologies. Expression of p53 was analysed by immunohistochemistry. DNA was extracted from frozen tumour tissues. TP53 mutations were detected in 48.8% of cases and were more frequent among SCCs than ADCs (p&lt;0.0001). TP53 mutation status was not associated with prognosis. G to T transversions, known to be associated with smoking, were marginally more common among patients who developed a second primary lung cancer or recurrence/metastasis (progressive disease). EGFR mutations were almost exclusively found in never-smoking females (p=0.0067). KRAS mutations were detected in 18.5% of cases, mainly ADC (p&lt;0.0001), and showed a tendency toward association with progressive disease status. These results suggest that mutations are good markers of different aetiologies and histopathological forms of lung cancers but have little prognostic value, with the exception of KRAS mutation, which may have a prognostic value in ADC.